Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
One-year data look encouraging, but etranadez will now not be filed until 2022.
A test that tracks response to therapy is useful, but approval and reimbursement will be key.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
The beleaguered big pharma is under huge pressure to change minds at Wednesday’s investor event.
Two huge up-front fees this week, for an anti-Tigit MAb and an antibody-drug conjugate, show that early-stage oncology assets are still hot.
The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
But data are early, and other groups are also developing less frequent injections for wet AMD.
Casirivimab plus imdevimab could at last add a hospitalised Covid-19 patient treatment string to their bow.
The data were statistically significant, but the market had been hoping for more.
But AZD7442 still has two more bites at the cherry.
A second clinical failure means that Biogen threw away $877m, but this sum will today be seen as little more than a rounding error.
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.
But with many Western markets already saturated, it is worth wondering how important Novavax’s Covid-19 jab will become.
As Arrowhead prepares to unveil key data in alpha-1 antitrypsin deficiency, its life is made easier by Vertex’s second failure in the disease.
But this week three transactions did squeak through.